The Foundation for Sarcoidosis Research (FSR) has invested $1 million in its new Clinical and Research Fellowship Program. It also gave travel awards to the first authors of the top four abstracts submitted for presentation at the annual conference of the Americas Association of Sarcoidosis and Other Granulomatous Disorders…
Radiotherapy may be useful for the control of sarcoidosis associated with bone involvement, according to a recent case report. “Emergency Radiotherapy for Spinal Cord Compression” was published in the journal Internal Medicine, a Japanese publication, and reports the case of a 68-year-old man complaining of right shoulder pain…
Treatment with Remicade (infliximab) in neurosarcoidosis patients is associated with favorable imaging and clinical treatment responses, new research shows. The study, “Infliximab for the treatment of CNS sarcoidosis,” was published in the journal Neurology. Neurosarcoidosis occurs in about 5% to 15% of patients with sarcoidosis…
Tumor necrosis factor (TNF) antagonists are effective therapies in a significant proportion of patients with severe and refractory sarcoidosis, a new study shows. However, they also are associated with adverse events such as infections and allergic reactions. The study titled, “Efficacy and safety of tumor necrosis factor…
A new study reports that 16.5% of sarcoidosis patients experience EDS (excessive daytime sleepiness), 16.4% experience severe fatigue, and 6.3% of patients report both symptoms. The study titled, “Fatigue and Excessive Daytime Sleepiness in Sarcoidosis: Prevalence, Predictors, and Relationships between the Two Symptoms,” was published in the journal…
Get regular updates to your inbox.